Summary: In adults with overweight or obesity participating in the STEP 1-4 Phase 3a trials over 68 weeks, once-weekly semaglutide…
Browsing: PICO
Summary: In adults with preexisting cardiovascular disease, overweight or obesity, and no prior diagnosis of diabetes, semaglutide (GLP-1 receptor agonist)…
Summary: In patients with type 2 diabetes and chronic kidney disease (CKD), weekly semaglutide 1.0 mg for a median of…
PICO Description Population Patients with obesity-related heart failure with preserved ejection fraction (HFpEF), enrolled in the STEP-HFpEF program, involving 1,145…
PICO Description Population Patients with type 2 diabetes and chronic kidney disease, defined by an estimated glomerular filtration rate (eGFR)…
Summary: In patients with obesity-related heart failure with preserved ejection fraction (HFpEF) enrolled in the STEP-HFpEF trials (n=1,145), weekly semaglutide…
Summary: In 1,879 adults with type 2 diabetes participating in the SURPASS-2 phase 3 trial conducted across 128 sites in…
Summary: In adults with early-onset type 2 diabetes (T2D) compared to those with later-onset T2D in a post hoc analysis…
Summary: In overweight or obese adults with type 2 diabetes (T2DM) and non-alcoholic fatty liver disease (NAFLD), combination therapy of…
Summary: In adults aged 18 years or older with obesity-related heart failure with preserved ejection fraction (HFpEF), characterized by a…